1. Home
  2. CGBD vs PHAT Comparison

CGBD vs PHAT Comparison

Compare CGBD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

N/A

Current Price

$11.20

Market Cap

826.2M

Sector

Finance

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$12.04

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGBD
PHAT
Founded
2012
2018
Country
United States
United States
Employees
2500
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
826.2M
894.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CGBD
PHAT
Price
$11.20
$12.04
Analyst Decision
Hold
Strong Buy
Analyst Count
8
6
Target Price
$12.92
$19.83
AVG Volume (30 Days)
685.7K
1.4M
Earning Date
05-11-2026
04-30-2026
Dividend Yield
14.42%
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$3.74
$93.04
Revenue Next Year
$1.80
$58.91
P/E Ratio
$10.36
N/A
Revenue Growth
N/A
216.93
52 Week Low
$10.64
$3.69
52 Week High
$14.48
$18.31

Technical Indicators

Market Signals
Indicator
CGBD
PHAT
Relative Strength Index (RSI) 42.87 48.15
Support Level $11.19 $10.38
Resistance Level $11.44 $12.52
Average True Range (ATR) 0.30 0.98
MACD -0.08 -0.01
Stochastic Oscillator 10.45 61.97

Price Performance

Historical Comparison
CGBD
PHAT

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: